The Global Diabetes Associated Ophthalmic Treatment Market accounted for US$ 26.14 Bn in 2020 with a considerable CAGR of 6.9% during the forecast period of 2021 to 2028.
Ophthalmic treatments are used in diagnosing and treating eye-related disorders. One suspected reason for eye-related disorders is diabetes. According to the International Diabetes Federation, in 2019, approximately 463 million adults were diagnosed with diabetes globally, and it is estimated to reach a whopping number of 700 million by 2045. Patients with diabetes damage their blood vessels located at the back of the eye, which can cause blindness if not treated in the early stages. This disorder in medical terms is referred to as diabetic retinopathy. Diabetic retinopathy (DR) is a major microvascular complication of diabetes that has a significant impact on the world’s health systems. The National Center for Biotechnology Information projects that the number of people suffering from diabetic retinopathy (DR) will reach around 190 million by 2030.
Market Dynamics
The growing prevalence of diabetes across the world is a primary factor for diabetes-associated ophthalmic treatment market growth. A rise in the geriatric population and growing incidences of blindness are other diabetes associated ophthalmic treatment market trends. The elderly population is among the worst hit with diabetic eye-related disorders. According to the World Population Ageing Report, the elderly population is projected to reach around 1.5 billion in 2050. Vision loss in the elderly is a common scenario owing to age-related macular degeneration, diabetic retinopathy, glaucoma, and cataract. There is an increasing awareness among the population regarding ophthalmic treatment and the benefits of early adoption of diabetic retinopathy. Thus increasing awareness will lead to early diagnosis of ophthalmic treatment ultimately contributing to higher demand.
Additionally, the growing demand for ophthalmic drugs related to diabetes will boost the demand during the forecast timeframe of 2021 to 2028. However, a limited number of skilled ophthalmologists and an extended approval time for ophthalmic drugs are the factors that might restrain the market from growing. Furthermore, support from several government organizations for diabetic treatments and heavy investments from private and public players further drives the demand for global diabetes associated ophthalmic treatment market during the review period from 2021 to 2028.
Report coverage
| Market |
Diabetes Associated Ophthalmic Treatment Market |
| Analysis Period |
2017 - 2028 |
| Base Year |
2020 |
| Forecast Data |
2021 - 2028 |
| Segments Covered |
By Application, By Type, By End Use, and By Geography |
| Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled |
Alcon, Allergan, Abbott Medical Optics, Bausch Health, Bayer AG, Carl Zeiss Meditec, Ellex Medical Lasers Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., IRIDEX Corp., Johnson & Johnson Services, Inc., Lumenis, Novartis AG, Pfizer, Inc., Quantel, Santen Pharmaceutical Co. Ltd., and Topcon Corp. among others.
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Customization Scope |
10 hrs of free customization and expert consultation
|
The growing prevalence of diabetes across the world
Diabetes is a chronic, progressive disease indicated by exalted levels of blood glucose. Diabetes causes vary depending on genetics, family history, health, and environmental factors. While, other factors such as excessive body-weight, inactivity, age, high blood pressure can also be leading factor to diabetes. According to a WHO report, diabetes is one of the four priority non-communicable diseases (NCDs) targeted for action by world leaders. Both the number of cases and prevalence of diabetes have been steadily increasing over the past few decades. The percentage of diabetes has nearly doubled since the late 80s, rising from 4.7% to 8.5% in the adult population. Over the past decade, the incidence of diabetes has witnessed a rapid growth in low and middle-income countries than in developed countries. Raised blood glucose levels, a common effect of uncontrolled diabetes, may eventually lead to serious damage to the eyes and other critical organs. Thus, ophthalmic treatments are on the rise as bulk patients suffering from diabetes cause eye-related disorders over time.
Market Segmentation
Global diabetes associated ophthalmic treatment market is segmented based on application, type, end-user, and region. Based on the application segment, the market classifies into diabetic retinopathy, diabetic macular edema, cataracts, glaucoma, eye allergy & infection, diabetic associated macular degeneration, uveitis, and others. Among applications, diabetic retinopathy acquired a maximum chunk in 2020. This is attributed to the high chances of diabetic patients being diagnosed with diabetic retinopathy, which may lead to vision loss over time. Based on the type, the segment bifurcates into drugs and devices. Among them, the drugs market accounted for the majority of the share in 2020, owing to the high adoption rate and key players operating in the global market. However, the devices sub-segment is anticipated to witness the highest growth during the forecast period of 2021 to 2028.
Moreover, the end-user segment is further sub-segmented into ophthalmic clinics, hospitals, ambulatory surgical centers, and others. Among the end-user segment, the hospital led the market with the utmost share in 2020 due to the presence of advanced medical facilities and emergency surgeries if required in a diabetic patient.
Regional Overview
North America region is expected to lead global diabetes associated ophthalmic treatment market during the projected period of 2021 to 2028
Among all the regions, North America generated the highest revenues in 2020. This is attributed to the presence of a high diabetic population in the United States. According to the Centers for Disease Control and Prevention (CDC) statistics 2020, there were 34.2 million people detected with diabetes i.e. (10.5% of the U.S. population). Additionally, the growing elderly population and high awareness among consumers in the region also propels the North American diabetes associated ophthalmic treatment market growth. Besides, the presence of well-established market players and growing demand for advanced healthcare facilities in the region also contributes towards the dominant share of the North American market. Meanwhile, the Asia-Pacific diabetes associated ophthalmic treatment market is anticipated to witness the fastest CAGR throughout the forecast period of 2021 to 2028. The market for APAC is growing because of the increasing number of diabetic patients in developing countries such as China and India. According to Diabetes Research and Clinical Practice, the number of diabetic patients in China and India summed up to 193.4 million in 2019. Moreover, the growing awareness in these countries and favorable government initiatives are also likely to surge the growth of the APAC market. For instance, the International Diabetes Federation has stressed the urgency to develop and implement multi-sectoral strategies to combat the growing epidemic.
Competitive Landscape
This section of the report pinpoints various key vendors of the market. Some of the key players offered in the report include Alcon, Allergan, Abbott Medical Optics, Bausch Health, Bayer AG, Carl Zeiss Meditec, Ellex Medical Lasers Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., IRIDEX Corp., Johnson & Johnson Services, Inc., Lumenis, Novartis AG, Pfizer, Inc., Quantel, Santen Pharmaceutical Co. Ltd., and Topcon Corp. among others.
Market Segmentation
Market By Application
- Diabetic Retinopathy
- Diabetic Macular Edema
- Cataracts
- Glaucoma
- Eye Allergy And Infection
- Diabetic Associated Macular Degeneration
- Uveitis
- Others
Market By Type
Market By End-User
- Ophthalmic Clinics
- Hospitals
- Ambulatory Surgical Centers
- Others
Market By Geography
- North America
- Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Diabetes Associated Ophthalmic Treatment
1.1. Definition and Scope
1.1.1. Definition of Diabetes Associated Ophthalmic Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Diabetes Associated Ophthalmic Treatment market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Diabetes Associated Ophthalmic Treatment By Application
1.2.3. Diabetes Associated Ophthalmic Treatment By Type
1.2.4. Diabetes Associated Ophthalmic Treatment By End-User
1.2.5. Diabetes Associated Ophthalmic Treatment by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Diabetes Associated Ophthalmic Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Diabetes Associated Ophthalmic Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Diabetic Macular Edema
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2019
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Diabetes Associated Ophthalmic Treatment By Application
4.1. Introduction
4.2. Diabetes Associated Ophthalmic Treatment Revenue By Application
4.2.1. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast, By Application, 2017-2028
4.2.2. Diabetic Retinopathy
4.2.2.1. Diabetic Retinopathy Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.3. Diabetic Macular Edema
4.2.3.1. Diabetic Macular Edema Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.4. Glaucoma
4.2.4.1. Glaucoma Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.5. Cataract
4.2.5.1. Cataract Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.6. Eye Allergy & Infection
4.2.6.1. Eye Allergy & Infection Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.7. Diabetic Associated Macular Degeneration
4.2.7.1. Diabetic Associated Macular Degeneration Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.8. Uveitis
4.2.8.1. Uveitis Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.9. Others
4.2.9.1. Others Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
CHAPTER 5. Diabetes Associated Ophthalmic Treatment By Type
5.1. Introduction
5.2. Diabetes Associated Ophthalmic Treatment Revenue By Type
5.2.1. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast, By Type, 2017-2028
5.2.2. Drugs
5.2.2.1. Drugs Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
5.2.3. Devices
5.2.3.1. Devices Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
CHAPTER 6. Diabetes Associated Ophthalmic Treatment Market By End-User
6.1. Introduction
6.2. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) By End-User
6.2.1. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
6.2.2. Ophthalmic Clinics
6.2.2.1. Ophthalmic Clinics Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.3. Hospitals
6.2.3.1. Hospitals Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.4. Ambulatory Surgical Centers
6.2.4.1. Ambulatory Surgical Centers Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.5. Others
6.2.5.1. Others Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
CHAPTER 7. North America Diabetes Associated Ophthalmic Treatment Market By Country
7.1. North America Diabetes Associated Ophthalmic Treatment Overview
7.2. U.S.
7.2.1. U.S. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
7.2.2. U.S. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
7.2.3. U.S. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
7.3. Canada
7.3.1. Canada Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
7.3.2. Canada Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
7.3.3. Canada Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
7.4. North America PEST Analysis
CHAPTER 8. Europe Diabetes Associated Ophthalmic Treatment Market By Country
8.1. Europe Diabetes Associated Ophthalmic Treatment Overview
8.2. U.K.
8.2.1. U.K. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
8.2.2. U.K. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
8.2.3. U.K. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.3. Germany
8.3.1. Germany Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
8.3.2. Germany Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
8.3.3. Germany Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.4. France
8.4.1. France Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
8.4.2. France Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
8.4.3. France Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.5. Spain
8.5.1. Spain Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
8.5.2. Spain Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
8.5.3. Spain Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.6. Rest of Europe
8.6.1. Rest of Europe Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
8.6.2. Rest of Europe Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
8.6.3. Rest of Europe Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Diabetes Associated Ophthalmic Treatment Market By Country
9.1. Asia Pacific Diabetes Associated Ophthalmic Treatment Overview
9.2. China
9.2.1. China Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.2.2. China Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
9.2.3. China Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.3. Japan
9.3.1. Japan Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.3.2. Japan Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
9.3.3. Japan Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.4. India
9.4.1. India Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.4.2. India Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
9.4.3. India Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.5. Australia
9.5.1. Australia Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.5.2. Australia Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
9.5.3. Australia Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.6. South Korea
9.6.1. South Korea Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.6.2. South Korea Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
9.6.3. South Korea Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
9.7.2. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
9.7.3. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Diabetes Associated Ophthalmic Treatment Market By Country
10.1. Latin America Diabetes Associated Ophthalmic Treatment Overview
10.2. Brazil
10.2.1. Brazil Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
10.2.2. Brazil Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
10.2.3. Brazil Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
10.3. Mexico
10.3.1. Mexico Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
10.3.2. Mexico Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
10.3.3. Mexico Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
10.4. Rest of Latin America
10.4.1. Rest of Latin America Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
10.4.2. Rest of Latin America Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
10.4.3. Rest of Latin America Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Diabetes Associated Ophthalmic Treatment Market By Country
11.1. Middle East & Africa Diabetes Associated Ophthalmic Treatment Overview
11.2. GCC
11.2.1. GCC Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
11.2.2. GCC Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
11.3. South Africa
11.3.1. South Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
11.3.2. South Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
11.3.3. South Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028
11.4.2. Rest of Middle East & Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028
11.4.3. Rest of Middle East & Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Diabetes Associated Ophthalmic Treatment
12.1. Diabetes Associated Ophthalmic Treatment Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Diabetes Associated Ophthalmic Treatment market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. COMPANY PROFILE
13.1. Alcon
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (US$ Bn), 2020
13.1.3.2. Alcon 2019 Diabetes Associated Ophthalmic Treatment Business Regional Distribution
13.1.4. Product/Service and Specification
13.1.5. Recent Developments & Business Strategy
13.1.6. Manufacturing Plant Footprint Analysis
13.2. Allergan
13.3. Abbott Medical Optics
13.4. Bausch Health
13.5. Bayer AG
13.6. Carl Zeiss Meditec
13.7. Ellex Medical Lasers Ltd.
13.8. F. Hoffmann-La Roche Ltd
13.9. Genentech, Inc.
13.10. Johnson & Johnson Services, Inc.
13.11. Lumenis
13.12. Novartis AG
13.13. Pfizer, Inc.
13.14. Quantel
13.15. Santen Pharmaceutical Co. Ltd.
13.16. Topcon Corp.
